Contract analysis

I. PURPOSE OF MEMORANDUM This memorandum serves as the formal matter closing record for Calderwood & Harkness LLP's ("C&H" or the "Firm") representation of Penterra Pharmaceuticals Corp. ("Penterra" or the "Client") in its declaratory-judgment action against Vantage Medical Distribution, LLC ("Vantage"), captioned Penterra Pharmaceuticals Corp. v. Vantage Medical Distribution, LLC, Docket No. 2184-CV-01537-BLS, in th

II. ENGAGEMENT SUMMARY A. Client and Engagement Team Client. Penterra Pharmaceuticals Corp. is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PTRA," with its principal executive offices located at 400 Carnegie Center Drive, Suite 600, Princeton, New Jersey 08540. Penterra is a mid-cap specialty pharmaceutical company focused on oncology, rare diseases, and immunolo

III. MATTER BACKGROUND AND FACTUAL SUMMARY A. The Parties' Relationship Penterra Pharmaceuticals Corp. is a mid-cap specialty pharmaceutical company with consolidated revenue of approximately $1.87 billion for fiscal year 2021. Penterra's product portfolio is concentrated in three therapeutic areas: oncology, rare diseases, and immunology. The company maintains a diversified distribution network across the United Sta

IV. PROCEDURAL HISTORY A. Pre-Litigation Phase On March 26, 2021, the Firm completed its conflict-of-interest check, which cleared the engagement with no identified conflicts. The engagement letter was executed on March 29, 2021, by Ms. Chao on behalf of Penterra and by Linda Osei on behalf of C&H. Promptly following engagement, C&H advised Penterra to issue and distribute a litigation hold notice to key custodians w

V. SUMMARY OF THE COURT'S DECISION A. Holding. The court's Memorandum of Decision and Order resolved all claims and counterclaims in the case. Specifically, the court held as follows:

1. The Territory under the EDA, as defined in Exhibit A, is limited to the six New England States enumerated therein: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont. The Territory does not encompass New York, New Jersey, or Pennsylvania.

2. The Kapoor Email did not constitute "prior written consent" by Penterra under Section 2.3 of the EDA for Vantage to distribute Products outside the Territory.

3. No amendment or modification to Exhibit A was ever executed in compliance with the written-amendment requirement of Section 13.1 of the EDA.

4. Vantage's counterclaim for breach of contract is dismissed on the merits, as Penterra did not breach the EDA by restricting Vantage's distribution activities to the contractually defined Territory.

5. Vantage's counterclaim for breach of the implied covenant of good faith and fair dealing is dismissed on the merits, as Penterra's actions were consistent with the express terms of the EDA.

6. Vantage's counterclaim for promissory estoppel is dismissed on the merits, as the Kapoor Email did not constitute a clear and definite promise, and Vantage's reliance was not reasonable in light of the EDA's integration clause and written-amendment requirements. B. Key Reasoning The court's analysis addressed each of the principal arguments raised by the parties and rested on the following key pillars of reasoning

VI. FINANCIAL SUMMARY A. Professional Fees Total professional fees billed to the Client over the course of the engagement were $894,320.00 (after application of the 7% discount). This figure represents the aggregate of all billable hours recorded by the engagement team at their respective discounted rates throughout the life of the matter, from the initial engagement in March 2021 through the completion of post-judgm

VII. KEY LESSONS LEARNED This section identifies key lessons and practice points arising from the engagement that may be of use to the Firm and to the Client in future matters. These observations are drawn from the substantive legal issues presented, the litigation strategy employed, and the practical dynamics of the case. A. Enforceability of Written-Modification Clauses Under Massachusetts Law The court's decision

Section 14.8 of the EDA — the integration clause — functioned effectively alongside Section 13.1 (the written-amendment requirement) to prevent Vantage from introducing extrinsic evidence of alleged oral or implied modifications to the EDA. The combination of these two provisions created a formidable contractual barrier to Vantage's claims. As a drafting best practice, integration clauses should be broadly worded and

VIII. RECOMMENDATIONS FOR FILE RETENTION AND CLOSING A. File Retention All physical and electronic files associated with matter number 1018-00007 should be retained in accordance with Calderwood & Harkness LLP's standard document retention policy. Consistent with the Firm's policy for concluded litigation matters, the minimum retention period for this matter shall be ten (10) years from the date of matter closing — i

1. Billing and Conflicts System. The matter status in the Firm's billing and conflicts management system should be changed from "Active" to "Closed" effective as of the date of this memorandum. The closing date should be recorded as September 12, 2022.

2. Invoice Confirmation. Confirm that all invoices rendered in connection with this matter have been paid in full by the Client. The final invoice, dated August 10, 2022, was transmitted by Priya Anand to Jennifer Chao. As of the date of this memorandum, no outstanding balances remain.

3. Case Tracking and Calendaring. Remove the matter from all active case tracking lists, calendaring systems, and court deadline monitoring databases maintained by the Firm. No further deadlines or filings are anticipated.

4. Experience Database. Update the Firm's internal experience and matter database to reflect the successful outcome of this engagement. The database entry should include the following key descriptors: declaratory judgment granted on summary judgment; all counterclaims dismissed; Massachusetts contract interpretation; pharmaceutical distribution; exclusive distribution agreement; territory dispute; written-amendment c

IX. APPROVALS AND SIGN-OFF This Matter Closing Memorandum has been prepared by the undersigned Lead Associate and is submitted to the Responsible Partner for review and approval. Upon approval, the matter will be formally closed in accordance with the Firm's policies and procedures. PREPARED BY: ________________________________________ Hannah Brinkley Lead Associate, Litigation Calderwood & Harkness LLP Date: _______